Acetylcholinesterase is critically involved in cognition, and acetylcholinesterase inhibitors are FDA-approved for the treatment of cognitive impairments in Alzheimer’s disease [37]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.